

Dit onderzoek is uitgevoerd binnen het Top Institute Pharma (project T6-301). De leden van het onderzoeksconsortium zijn de Universiteit Utrecht, het College ter Beoordeling van Geneesmiddelen en Nefarma. De meningen in dit artikel zijn uitsluitend die van de auteurs en op geen enkele wijze te interpreteren of te citeren als die van het College ter Beoordeling van Geneesmiddelen, andere agentschappen, een van hun comités of werkgroepen.

P.J.K. van Meer heeft geen conflicterende belangen. H. Schellekens heeft deelgenomen aan congressen en publicaties gesponsord door Amgen, Johnson & Johnson, Roche, Sandoz en Hospira. Een deel van zijn onderzoek wordt direct of indirect gesponsord door Roche en Amgen.

## Literatuur

- Baldrick P. Safety evaluation of biological drugs: what are toxicology studies in primates telling us? *Regul Toxicol Pharmacol*. 2011 mrt;59(2):227-36.
- Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. *Nephrol Dial Transplant*. 2005 jun;20 Suppl 6:vi3-9.
- Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. *Clin Ther*. 2002 nov;24(11):1720-40; discussion 1719.
- Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. *Nephrol Dial Transplant*. 2006 okt;21 Suppl 5:v9-12.
- Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. *Curr Opin Rheumatol*. 2009 mei;21(3):211-5.
- De Groot AS, Knopp PM, Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. *Dev Biol (Basel)*. 2005;122:171-94.
- Bugelski PJ, Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. *Curr Opin Mol Ther*. 2004 feb;6(1):10-6.
- Descotes J. Immunotoxicity of monoclonal antibodies. *MAbs*. 2009 mrt-apr;1(2):104-11.
- Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(r1). Genève: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2011 jun 12. [www.ich.org/fileadmin/Public\\_Web\\_Site/ICH\\_Products/Guidelines/Safety/S6\\_R1/Step4/S6\\_R1\\_Guideline.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf). Geraadpleegd 2014 nov 3.
- Committee for Medicinal products for Human Use. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London: European Medicines Agency; 2007 dec 13. [www.ema.europa.eu/ema/pages/includes/document/open\\_document.jsp?webContentId=WC500003946](http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003946). Geraadpleegd 2014 nov 3.
- Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. *Pharm Res*. 2011 okt;28(10):2379-85.
- Wierda D, Smith HW, Zwickl CM. Immunogenicity of biopharmaceuticals in laboratory animals. *Toxicology*. 2001 feb 2;158(1-2):71-4.
- Ponce R, Abad L, Amaravadi L, et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. *Regul Toxicol Pharmacol*. 2009 jul;54(2):164-82.
- Swanson SJ, Bussiere J. Immunogenicity assessment in non-clinical studies. *Curr Opin Microbiol*. 2012 jun;15(3):337-47.
- Gorovits B. Antidrug antibody assay validation: industry survey results. *AAPS J*. 2009 mrt;11(1):133-8.
- Hwang WY, Foote J. Immunogenicity of engineered antibodies. *Methods*. 2005 mei;36(1):3-10.
- Bartelds GM, Kriekaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. *JAMA*. 2011 apr 13;305(14):1460-8.
- de Vries MK, Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. *Ann Rheum Dis*. 2007 sep;66(9):1252-4.
- Isaacs JD, Manna VK, Rapson N, et al. CAMPATH-1H in rheumatoid arthritis – an intravenous dose-ranging study. *Br J Rheumatol*. 1996 mrt;35(3):231-40.
- Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD. Have we overestimated the benefit of human(ized) antibodies? *MAbs*. 2010 nov-dec;2(6):682-94.
- Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? *Immunol Today*. 2000 aug;21(8):397-402.
- Büttel IC, Chamberlain P, Chowder Y, et al. Taking immunogenicity assessment of therapeutic proteins to the next level. *Biologicals*. 2011 mrt;39(2):100-9.
- Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans – clinical significance, assessment and prediction. *Curr Pharm Biotechnol*. 2002 dec;3(4):349-60.
- Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. *Nat Biotechnol*. 2007 mei;25(5):555-61.
- Wadhwa M, Thorpe R. Strategies and assays for the assessment of unwanted immunogenicity. *J Immunotoxicol*. 2006 sep 1;3(3):115-21.
- Chapman K, Pullen N, Coney L, et al. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. *MAbs*. 2009 sep-okt;1(5):505-16.
- Schellekens H. The immunogenicity of therapeutic proteins. *Discov Med*. 2010 jun;9(49):560-4.
- Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. *Blood*. 2002 mrt 15;99(6):2054-9.

## Verbetering

In *PW Wetenschappelijk Platform* van 23 januari 2015 [9(1):8] is in het referaat 'Interactie tussen erlotinib en zuurremmers' de eerste alinea verminkt.

Die had moeten beginnen met:

Over sommige in de G-Standaard gemelde interacties is discussie. Zo is er twijfel over het belang van de interactie tussen (es)omeprazol en clopidogrel [1].